Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

IMW 2019 | Using immunopaths to image residual disease

Ola Landgren • 15 Sep 2019
IMW 2019
Multiple Myeloma Daratumumab

Ola Landgren, MD, PhD, of Memorial Sloan Kettering Cancer Center, New York, NY, discusses his research into immunopaths and describes the method by which he was successful in imaging potential residual disease that would not otherwise have been visible using blood tests or biopsies. This interview was recorded at the international myeloma workshop (IMW) 2019, in Boston, MA.

More from Ola Landgren

The iMMunoPET trial: 89Zr-DFO-daratumumab for CD38-targeted imaging of multiple myeloma 4:45
The iMMunoPET trial: 89Zr-DFO-daratumumab for CD38-targeted imaging of multiple myeloma
Ola Landgren • 6 Dec 2025
Trends in the evolving myeloma treatment landscape: observations from ASCO 2025 3:42
Trends in the evolving myeloma treatment landscape: observations from ASCO 2025
Ola Landgren • 6 Jun 2025
An update on the ADVANCE trial comparing Dara-KRd versus KRd in newly diagnosed myeloma 3:38
An update on the ADVANCE trial comparing Dara-KRd versus KRd in newly diagnosed myeloma
Ola Landgren • 6 Jun 2025
Where is the smoldering myeloma field moving, and what does future management look like? 4:02
Where is the smoldering myeloma field moving, and what does future management look like?
Ola Landgren • 6 Jun 2025

Related Videos

Belantamab mafodotin in functional high-risk RRMM: subgroup analysis of DREAMM-7 and DREAMM-8 4:02
Belantamab mafodotin in functional high-risk RRMM: subgroup analysis of DREAMM-7 and DREAMM-8
Meral Beksac • 10 Dec 2025
Incidence and risk factors for infections in NDMM treated with modern induction regimens 1:54
Incidence and risk factors for infections in NDMM treated with modern induction regimens
Efstathios Kastritis • 7 Dec 2025
A real-world analysis of infections in patients with RRMM receiving ide-cel 3:59
A real-world analysis of infections in patients with RRMM receiving ide-cel
Muhammad Bilal Abid • 6 Dec 2025
Integrating molecular diagnostics in smoldering myeloma to predict disease progression 1:37
Integrating molecular diagnostics in smoldering myeloma to predict disease progression
Gareth Morgan • 7 Dec 2025
The content of VJHemOnc is intended for healthcare professionals